Vivo Capital’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.4M | Buy |
6,694,637
+27,971
| +0.4% | +$125K | 3.23% | 11 |
|
|
2026
Q1 | $25M | Sell |
6,666,666
-2,222,222
| -25% | -$7.5M | 2.08% | 16 |
|
|
2025
Q4 | $26.8M | Hold |
8,888,888
| – | – | 1.73% | 19 |
|
|
2025
Q3 | $16.9M | Hold |
8,888,888
| – | – | 1.36% | 23 |
|
|
2025
Q2 | $12.6M | Hold |
8,888,888
| – | – | 1.29% | 14 |
|
|
2025
Q1 | $13.6M | Hold |
8,888,888
| – | – | 1.8% | 8 |
|
|
2024
Q4 | $22M | Buy |
+8,888,888
| New | +$22.1M | 2.47% | 7 |
|
|
2023
Q4 | – | Sell |
-898,631
| Closed | -$6.16M | – | 49 |
|
|
2023
Q3 | $6.16M | Hold |
898,631
| – | – | 0.67% | 34 |
|
|
2023
Q2 | $9.32M | Hold |
898,631
| – | – | 0.64% | 25 |
|
|
2023
Q1 | $7.27M | Hold |
898,631
| – | – | 0.5% | 25 |
|
|
2022
Q4 | $14.2M | Hold |
898,631
| – | – | 1.63% | 18 |
|
|
2022
Q3 | $14.1M | Hold |
898,631
| – | – | 1.56% | 20 |
|
|
2022
Q2 | $12.5M | Hold |
898,631
| – | – | 1.26% | 22 |
|
|
2022
Q1 | $15.5M | Sell |
898,631
-22,351
| -2% | -$305K | 1.07% | 22 |
|
|
2021
Q4 | $13.4M | Sell |
920,982
-19,772
| -2% | -$300K | 0.81% | 29 |
|
|
2021
Q3 | $16.9M | Sell |
940,754
-433,525
| -32% | -$6.95M | 0.76% | 26 |
|
|
2021
Q2 | $24.1M | Sell |
1,374,279
-272,935
| -17% | -$6.2M | 1.04% | 23 |
|
|
2021
Q1 | $41.5M | Hold |
1,647,214
| – | – | 1.46% | 15 |
|
|
2020
Q4 | $10.7M | Hold |
1,647,214
| – | – | 0.48% | 39 |
|
|
2020
Q3 | $4.23M | Hold |
1,647,214
| – | – | 0.24% | 54 |
|
|
2020
Q2 | $2.67M | Hold |
1,647,214
| – | – | 0.19% | 51 |
|
|
2020
Q1 | $1.71M | Buy |
+1,647,214
| New | +$2.24M | 0.16% | 48 |
|
|
2019
Q3 | – | Sell |
-1,647,214
| Closed | -$3.61M | – | 6 |
|
|
2019
Q2 | $3.61M | Hold |
1,647,214
| – | – | 0.34% | 38 |
|
|
2019
Q1 | $9.87M | Hold |
1,647,214
| – | – | 0.98% | 26 |
|
|
2018
Q4 | $12.2M | Hold |
1,647,214
| – | – | 1.55% | 18 |
|
|
2018
Q3 | $23.9M | Hold |
1,647,214
| – | – | 2.41% | 15 |
|
|
2018
Q2 | $32.9M | Hold |
1,647,214
| – | – | 4.24% | 5 |
|
|
2018
Q1 | $28.9M | Hold |
1,647,214
| – | – | 4.09% | 7 |
|
|
2017
Q4 | $40.6M | Sell |
1,647,214
-1,211,355
| -42% | -$29.5M | 8.7% | 3 |
|
|
2017
Q3 | $73.8M | Hold |
2,858,569
| – | – | 14.91% | 2 |
|
|
2017
Q2 | $77.5M | Hold |
2,858,569
| – | – | 19.52% | 1 |
|
|
2017
Q1 | $85.2M | Sell |
2,858,569
-425,000
| -13% | -$12.3M | 25.08% | 1 |
|
|
2016
Q4 | $89.1M | Sell |
3,283,569
-907,828
| -22% | -$23.1M | 29.37% | 1 |
|
|
2016
Q3 | $107M | Hold |
4,191,397
| – | – | 33.45% | 1 |
|
|
2016
Q2 | $77.4M | Hold |
4,191,397
| – | – | 21.14% | 2 |
|
|
2016
Q1 | $79.4M | Buy |
+4,191,397
| New | +$80.1M | 19.92% | 1 |
|
Other funds holding ACRS
RCM
BCM
DTC
FLSM
RSCM
DC
Vivo Capital's ACRS Position: Q2 2026 in Review
Vivo Capital increased its Aclaris Therapeutics (ACRS) stake by 0.42% in Q2 2026, buying an estimated $125K and bringing the position to 6,694,637 shares worth $35.4M. The position accounts for 3.23% of the portfolio, ranked #11.
Vivo Capital first reported a position in ACRS in Q1 2016 and has held it in 36 quarters since. The position peaked at $107M in Q3 2016. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.
- Vivo Capital held 6,694,637 shares of Aclaris Therapeutics worth $35.4M as of Q2 2026.
- Vivo Capital bought 27,971 Aclaris Therapeutics shares in Q2 2026, an estimated $125K.
- Aclaris Therapeutics made up 3.23% of Vivo Capital's portfolio in Q2 2026, its #11 holding.
- Vivo Capital first reported a position in Aclaris Therapeutics in Q1 2016 and has held it in 36 quarters since.
- Vivo Capital's Aclaris Therapeutics position peaked at $107M in Q3 2016.
- 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.
Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.